Related Experiment Video
Updated: Dec 28, 2025
08:41
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
1.6K
Therapeutic Landscape for NAFLD in 2020.
1Division of Gastroenterology and Hepatology, Saint Louis University, St Louis, Missouri.
Gastroenterology
|February 17, 2020
Summary
Lifestyle changes are difficult for nonalcoholic steatohepatitis (NASH) patients. New drug therapies targeting liver injury, inflammation, and fibrosis are in development to combat NASH and its severe complications.
Area of Science:
- Hepatology
- Gastroenterology
- Pharmacology
Background:
- Nonalcoholic steatohepatitis (NASH) is a growing health concern.
- Lifestyle modifications like diet and exercise are primary recommendations but often fail.
- NASH can lead to severe liver disease, including cirrhosis and cancer.
Purpose of the Study:
- To review the current treatment landscape for NASH.
- To highlight pharmacological interventions in Phase 2 and Phase 3 clinical trials.
- To discuss the potential for personalized therapy in NASH management.
Main Methods:
- Review of clinical trials for NASH pharmacotherapies.
- Analysis of drugs targeting various pathogenic mechanisms of NASH.
- Focus on agents in Phase 2 and Phase 3 development.
Main Results:
- Multiple pharmacological targets are being investigated for NASH.
- Drugs aim to reduce energy imbalance, lipotoxicity, inflammation, and fibrosis.
- Promising agents are progressing through late-stage clinical trials.
Conclusions:
- Pharmacological interventions are crucial for managing NASH.
- Future NASH treatment may involve personalized approaches based on individual mechanisms.
- Continued research and clinical trials are essential for effective NASH therapies.
More Related Videos
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
243
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
243
01:24Nephrotic Syndrome III : Nursing Management
234
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
234
01:26Nephrotic Syndrome II : Assessment and Medical Management
155
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
155
01:26Atherosclerosis III: Management
277
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
277
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
436
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
436
01:24Nephrotic Syndrome I : Introduction
417
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
417